Inside EU Health Inside EU Health: US tariffs and MFN pricing threaten EU investment and access; EMA and FDA agree good AI; ECDC issues warning on Doxy-PEP Inside EU Health: US tariffs and MFN pricing threaten EU investment and access; EMA and FDA agree good AI principles; ECDC issues warning on Doxy-PEP
EU/US Trade US tariffs and MFN pricing threaten pharma investment and access in Europe Rising uncertainty driven by US tariffs and proposed “most-favoured nation” pricing is prompting pharmaceutical companies to delay investment and product launches in Europe
